+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bronchitis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 117 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5713474

Industry Outlook

Bronchitis treatment market accounted for a market value of US$ 3,509.7 Mn in 2021 and is projected to grow at a CAGR of 4.9% during the forecast period from 2022 to 2030. Bronchitis treatment market is growing gradually throughout the forecast period due to strong product pipeline equipped with target-specific drugs, and rising prevalence & awareness related to the treatment & diagnosis of bronchitis. The major cause of bronchitis is frequent cigarette smoking coupled with exposure to air-pollutants. Thus, overall growth of global bronchitis treatment is significant and expected to maintain its growth throughout the forecast year with the help of upcoming drugs currently present under trials.

Continuous research & development in the field of bronchitis treatment expected to bring novel drugs in the market & ultimately assist the overall growth

During the forecast period from 2022 to 2030, phospodiesterase-4inhibitors identified as the fastest growing segment due to major factors such as Roflumilast are beneficial in chronic bronchitis to decrease exacerbations & relieve dyspnea, and physicians treat chronic bronchitis on priority as its more complex compared to acute bronchitis. Roflumilast also plays key role in improving the lung function and assists recovery of patients. Thus, novel drugs entering in the market will increase the growth of overall bronchitis treatment market, as there is huge market demand for target-specific drugs in the market.

Increasing prevalence & awareness related to the bronchitis in Asia Pacific makes it the fastest growing region throughout the forecast period

The Asia Pacific will grow significantly throughout the forecast period from 2022 to 2030, the key factors responsible for growth of bronchitis treatment market in this region are rising prevalence of bronchitis due to high level of air-pollution & smoking population, and increasing awareness and accessibility related to bronchitis treatment. There are several awareness campaigns carried out by government and non-government organizations in developing countries of Asia Pacific such as China, India, Indonesia, and Thailand due to which bronchitis treatment market is growing significantly in this region. China & India have highest population suffering with bronchitis that mainly caused due to air-pollution and huge cigarette smoking population. According to World Health Organization (WHO), it has been recorded that in Asia around one third or 2.2 million of the world's 7 million premature deaths occur due to respiratory disorders caused due to air-pollution each year.

The key manufacturers present in the market reported based on product portfolio, current market updates, financial information, and key strategies. This report also include attractive investment proposition studied with the aid of PESTEL analysis, which based on detailed geographical research. Major companies studied in the overall report are AstraZeneca Plc, DBV Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., and Mucosis BV among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Bronchitis Treatment market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Bronchitis Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • Antitussives/ Expectorants
  • Bronchodilators
  • Beta-adrenergic Agonist
  • Systemic Corticosteroids
  • Inhaled Corticosteroids
  • Phosphodiesterase-4 Inhibitors
  • Analgesics
  • Antibiotics

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Bronchitis Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Bronchitis Treatment market?
  • Which is the largest regional market for Bronchitis Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Bronchitis Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Bronchitis Treatment market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Bronchitis Treatment Market
2.2. Global Bronchitis Treatment Market, By Drug Class, 2021 (US$ Million)
2.3. Global Bronchitis Treatment Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021

3. Bronchitis Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Bronchitis Treatment Market Vendors
3.2. Strategies Adopted by Bronchitis Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030

4. Bronchitis Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Bronchitis Treatment Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Antitussives/ Expectorants
5.3.2. Bronchodilators
5.3.3. Beta-adrenergic Agonist
5.3.4. Systemic Corticosteroids
5.3.5. Inhaled Corticosteroids
5.3.6. Phosphodiesterase-4 Inhibitors
5.3.7. Analgesics
5.3.8. Antibiotics

6. North America Bronchitis Treatment Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
6.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)

7. UK and European Union Bronchitis Treatment Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)

8. Asia Pacific Bronchitis Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
8.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)

9. Latin America Bronchitis Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
9.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)

10. Middle East and Africa Bronchitis Treatment Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
10.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)

11. Company Profile
11.1. Advanced Inhalation Therapies (AIT) Ltd.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. AstraZeneca Plc
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. DBV Technologies SA
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. F. Hoffmann-La Roche Ltd.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Han Wha Pharma Co. Ltd.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Kyorin Pharmaceutical Co Ltd.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Merck & Co.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Mucosis BV
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Orbis Biosciences, Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Therabron Therapeutics, Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. GlaxoSmithKline plc
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Chong Kun Dang Pharmaceutical
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. ONY Biotech Inc.
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
11.14. Genentech, Inc.
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Portfolio
11.14.4. Strategic Initiatives
11.15. Daewon Pharm Co. Ltd.
11.15.1. Company Overview
11.15.2. Financial Performance
11.15.3. Product Portfolio
11.15.4. Strategic Initiatives

List of Figures
Figure 1 Global Bronchitis Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Bronchitis Treatment Market: Quality Assurance
Figure 5 Global Bronchitis Treatment Market, By Drug Class, 2021
Figure 6 Global Bronchitis Treatment Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Bronchitis Treatment Market, 2021
Figure 8 Market Positioning of Key Bronchitis Treatment Market Players, 2021
Figure 9 Global Bronchitis Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Bronchitis Treatment Market, By Drug Class, 2021 Vs 2030, %
Figure 11 U.S. Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 12 Canada Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 14 UK Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 15 Germany Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 16 Spain Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 17 Italy Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 18 France Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 20 China Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 21 Japan Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 22 India Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 23 Australia Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 24 South Korea Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 26 Brazil Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 27 Mexico Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 29 GCC Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 30 Africa Bronchitis Treatment Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Bronchitis Treatment Market (US$ Million), 2020 - 2030

List of Tables
Table 1 Global Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 2 North America Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 3 U.S. Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 4 Canada Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 5 Rest of North America Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 6 UK and European Union Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 7 UK Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 8 Germany Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 9 Spain Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 10 Italy Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 11 France Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 12 Rest of Europe Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 13 Asia Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 14 China Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 15 Japan Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 16 India Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 17 Australia Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 18 South Korea Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 19 Latin America Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 20 Brazil Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 21 Mexico Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 22 Rest of Latin America Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 23 Middle East and Africa Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 24 GCC Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 25 Africa Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)

Companies Mentioned

  • AstraZeneca Plc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd.
  • Han Wha Pharma Co. Ltd.
  • Mucosis